Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity

References

• Bowersock TL, Martin S. 1999. Vaccine delivery to animals. Adv Drug Deliv Rev. 38 2: 167–194.
   PubMed Web of Science ®Google Scholar
• Coeshott CM, Smithson SL, Verderber E, Samaniego A, Blonder JM, Rosenthal GJ, Westerink MAJ. 2004. Pluronic@F127-based systemic vaccine delivery systems. Vaccine. 22 19: 2396–2405.
   PubMed Web of Science ®Google Scholar
• Gong C, Qian Z, Liu C, Huang M, Gu Y, Wen Y, Kan B, Wang K, Dai M, Li X, Gou M, Tu M, Wei Y. 2007. A thermosensitive hydrogel based on biodegradable amphiphilic poly(ethylene glycol)-polycaprolactone-poly(ethylene glycol) block copolymers. Smart Mater Struct. 16 3: 927–933.
   Web of Science ®Google Scholar
• Gong C, Shi S, Dong P, Kan B, Gou M, Wang X, Li X, Luo F, Zhao X, Wei Y, Qian Z. Synthesis and characterization of PEG-PCL-PEG thermosensitive hydrogel. Int J Pharm. 2009a; 365 1–2: 89–99.
   PubMed Web of Science ®Google Scholar
• Gong C, Shi S, Dong P, Zheng X, Fu S, Guo G, Yang J, Wei Y, Qian Z. In vitro drug release behavior from a novel thermosensitive composite hydrogel based on Pluronic f127 and poly(ethylene glycol)-poly(epsilon-caprolactone)-poly(ethylene glycol) copolymer. BMC Biotechnol. 2009b; 9 1: 8.
   PubMedGoogle Scholar
• Gou M, Huang M, Qian Z, Yang L, Dai M, Li X, Wang K, Wen Y, Li J, Zhao X, Wei Y. 2007. Preparation of anionic poly(ε-caprolactone)-poly(ethylene glycol)-poly(ε-caprolactone) copolymeric nanoparticles as basic protein antigen carrier. Growth Factors. 25 3: 202–208.
   PubMed Web of Science ®Google Scholar
• Gou M, Dai M, Gu Y, Li X, Wen Y, Yang L, Wang K, Wei Y, Qian Z. BFGF loaded biodegradable PCL-PEG-PCL copolymeric nanoparticles: Preparation, in vitro release and immunogenicity study. J Nanosci Nanotechnol. 2008a; 8:1–5.
   PubMed Web of Science ®Google Scholar
• Gou M, Dai M, Li X, Yang L, Huang M, Wang Y, Kan B, Lu Y, Wei Y, Qian Z. Preparation of mannan modified anionic PCL-PEG-PCL nanoparticles at one-step for bFGF antigen delivery to improve humoral immunity. Colloids Surf B Biointerfaces. 2008b; 64 1: 135–139.
   PubMed Web of Science ®Google Scholar
• Gupta RK. 1998. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev. 32 3: 155–172.
   PubMed Web of Science ®Google Scholar
• Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CK. 1993. Adjuvants – A balance between toxicity and adjuvanticity. Vaccine. 11 3: 293–306.
   PubMed Web of Science ®Google Scholar
• Hanes J, Cleland JL, Langer R. 1997. New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev. 28 1: 97–119.
   PubMed Web of Science ®Google Scholar
• Julie Westerink MA, Louise Smithson S, Srivastava N, Blonder J, Coeshott C, Rosenthal GJ. 2001. ProJuvantTM (Pluronic F127@/chitosan) enhances the immune response to intranasally administered tetanus toxoid. Vaccine. 20 5–6: 711–723.
   PubMed Web of Science ®Google Scholar
• Kang ML, Jiang H-L, Kang SG, Guo DD, Lee DY, Cho C-S, Yoo HS. 2007. Pluronic@F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine. 25 23: 4602–4610.
   PubMed Web of Science ®Google Scholar
• Liu MA. 1999. Topic in review: Vaccines in the 21st century. West J Med. 171 5–6: 319–322.
   PubMedGoogle Scholar
• Liu J-Y, Wei Y-Q, Yang L, Zhao X, Tian L, Hou J-M, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su J-M, Lou Y-Y, He Q-M, Wen Y-J, Yang J-L, Kan B, Mao Y-Q, Luo F, Peng F. 2003. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood. 102 5: 1815–1823.
   PubMed Web of Science ®Google Scholar
• Lu Y, Wei Y-Q, Tian L, Zhao X, Yang L, Hu B, Kan B, Wen Y-J, Liu F, Deng H-X, Li J, Mao Y-Q, Lei S, Huang M-J, Peng F, Jiang Y, Zhou H, Zhou L-Q, Luo F. 2003. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol. 170 6: 3162–3170.
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Rappuoli R. 2004. The safety of vaccines. Drug Discov Today. 9 19: 846–854.
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, Rappuoli R. 2006. Novel approaches to pediatric vaccine delivery. Adv Drug Deliv Rev. 58 1: 29–51.
   PubMed Web of Science ®Google Scholar
• O'Hagan DT, MacKichan ML, Singh M. 2001. Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 18 3: 69–85.
   PubMedGoogle Scholar
• Plum SM, Holaday JW, Ruiz A, Madsen JW, Fogler WE, Fortier AH. 2000. Administration of a liposomal FGF-2 peptide vaccine leads to abrogation of FGF-2-mediated angiogenesis and tumor development. Vaccine. 19 9–10: 1294–1303.
   PubMed Web of Science ®Google Scholar
• Poland GA, Murray D, Bonilla-Guerrero R. 2002. Science, medicine, and the future: New vaccine development. BMJ. 324 7349: 1315–1319.
   PubMedGoogle Scholar
• Singh M, O'Hagan DT. 1999. Advances in vaccine adjuvants. Nat Biotech. 17 11: 1075–1081.
   PubMed Web of Science ®Google Scholar
• Singh M, O'Hagan DT. 2002. Recent advances in vaccine adjuvants. Pharm Res. 19 6: 715–728.
   PubMed Web of Science ®Google Scholar
• Wang L-L, Li J-J, Zheng Z-B, Liu H-Y, Du G-J, Li S. 2004. Antitumor activities of a novel indolin-2-ketone compound, Z24: More potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells. Eur J Pharmacol. 502 1–2: 1–10.
   PubMed Web of Science ®Google Scholar
• Wei Y-Q, Wang Q-R, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu C-J, Huang M-J, Lou Y-Y, Xiao F, He Q-M, Shu J-M, Xie X-J, Mao Y-Q, Lei S, Luo F, Zhou L-Q, Liu C-E, Zhou H, Jiang Y. 2000. Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine. Nat Med. 6 10: 1160–1166.
   PubMed Web of Science ®Google Scholar
• Wei Y-Q, Huang M-J, Yang L, Zhao X, Tian L, Lu Y, Shu J-M, Lu C-J, Niu T, Kang B, Mao Y-Q, Liu F, Wen Y-J, Lei S, Luo F, Zhou L-Q, Peng F, Jiang Y, Liu J-Y, Zhou H, Wang Q-R, He Q-M, Xiao F, Lou Y-Y, Xie X-J, Li Q, Wu Y, Ding Z-Y, Hu B, Hu M, Zhang W. 2001. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci. 98 20: 11545–11550.
   PubMed Web of Science ®Google Scholar
• Weich HA, Iberg N, Klagsbrun M, Folkman J. 1990. Expression of acidic and basic fibroblast growth factors in human and bovine vascular smooth muscle cells. Growth Factors. 2 4: 313–320.
   PubMedGoogle Scholar